Posted: 14 Mar 2018 07:30 PM PDT roundup of other recent state laws). The Prescription Drug Price Transparency Act, H.B. 4005, places new reporting requirements on drug manufacturers related to price increases and patient assistance programs. Insurers are also required to report certain information about prescription drugs use and costs to the Department of Consumer and Business Services. On March 13, 2018, Oregon became the latest state to enact a law focused on transparency in drug pricing (see our Manufacturer Reports Under Oregon’s new law, manufacturers must report certain information for each prescription drug that has a price of $100 or more for a one-month supply or for a course of treatment lasting less than one month, and that had a net increase of 10% or more in the price over the course of the previous calendar year. Price is defined as the wholesale acquisition cost. By July 1, 2019, and by March 15 of every year thereafter, manufacturers must report extensive pricing and cost information for each such drug, including:
The new law includes an element of public shaming. The Oregon Department of Consumer and Business Services will post a list of the prescription drugs that have net increases of more than 10% on its website. In addition, the information provided by the manufacturers will be posted on the same website. Trade secrets protected under Oregon’s public records law may not be posted on the website, if “the public interest does not require disclosure of the information.” There is no further elaboration concerning circumstances in which the public interest may justify posting of trade secret information. The Department is also going to develop a process for consumers to notify the state about an increase in the price of a prescription drug. Insurer Reports Oregon is not only seeking pricing information from manufacturers. Under the new law, insurers must report:
As we have previously reported, in the absence of federal action, a growing number of states are seeking to limit drug costs through legislation. Some states have focused on marketing prohibitions and/or limitations on payments to practitioners (for example, see our post on New Jersey’s new limits). Other states, like Oregon, have focused on drug prices, with some states enacting requirements for reporting or outright restrictions on price increases on certain drugs (for example, Marylandand Vermont). Many of the new state drug price reporting laws are facing legal challenges that argue these laws are unconstitutional (see our coverage of the challenges to laws in Maryland, Nevada, and California). Due to the amount of information that manufacturers are required to report under the new Oregon law, and the fact that this information will be made available to the public, we anticipate that similar legal challenges may be raised before the new Oregon law goes into effect. We will continue to monitor this law and similar developments in other states. |
jueves, 15 de marzo de 2018
Oregon Jumps on the Drug Pricing Transparency Bandwagon
Oregon Jumps on the Drug Pricing Transparency Bandwagon
![Link to FDA Law Blog](https://blogger.googleusercontent.com/img/proxy/AVvXsEgoq6QPi8ifV6eDC2LskNx4W0gFisAVD28zHi_hMCYMcFRQWt0JK6F2JLUgfOF1kUrc1PMyFeznt7TbW9Ll9rMGgnd-1CibRcZtVoFnpcZ8cxv-nfDaaOOODp7wDnbvqgYspGEI4sD7XpdVK-CbnNNCvmGwzD0AdUVPSY3QK_B0eug=s0-d-e1-ft)
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario